Cerebral small vessel disease (SVD) is quite a common finding on computer tomography (CT) and magnetic resonance imaging (MRI) scans of older people. SVD includes white matter lesions (WML) and lacunar infarcts, which are frequently associated to cardiovascular factors such as hypertension, diabetes mellitus and atrial fibrillation (AF). Interestingly, patients with WML present an […]
Category: Uncategorized
On track for better outcomes: in vivo analysis of white matter pathways to enhance neuro-oncological practice
Starting from the early 19th Century, white matter fibre pathways have been increasingly recognised as integral to brain function. Since this time, the development of non-invasive advanced MRI techniques such as diffusion tractography (DT) has allowed the intricate architecture of these networks to be further unravelled and the complexity that these pathways contribute to human […]
Deep brain stimulation in dystonia: is it a long-term effective and safe treatment?
In the November issue of JNNP, Meoni and colleagues have published an interesting observational retrospective study exploring the long-term effect of pallidal deep brain stimulation (DBS) on motor and functional disability in patients with idiopathic, inherited and acquired dystonia. DBS is a neuromodulatory strategy base on a brain implanted electronic device used to modulate […]
Cognitive impairment in Parkinson’s disease: is there finally an accessible biomarker?
In the October issue of JNNP, Lin and colleagues explore plasma levels of a-synuclein as a biomarker in patients with varying stages of Parkinson’s disease (PD), across both motor and non-motor domains.The extensive evaluation of biofluids in the hunt for diagnostic and prognostic biomarkers in PD has been disappointing and largely inconclusive to date. Studies […]
The cerebellum in neurodegeneration: more than just balance control
In the current issue of JNNP, Gellersen and colleagues have published the first meta-analysis designed to assess patterns of cerebellar atrophy across different neurodegenerative diseases. Typically, neurodegenerative diseases have been linked to impairment in cortical and basal ganglia structures, however increasing evidence suggests that degeneration in the cerebellum also plays a role in these […]
Cognitive profiling in bvFTD and ALS-bvFTD: is there a difference?
In the August issue of JNNP, Saxon and colleagues analyse the cognitive characteristics of pure behavioural variant FTD (bvFTD) and compare this to the behavioural and cognitive symptoms that develop in a proportion of amyotrophic lateral sclerosis (ALS) patients (ALS-bvFTD). The occurrence of cognitive impairment is now well recognised in ALS, and the clinical and […]
Anti-neurofascin-155 antibodies: dissecting peripheral nerve abnormalities in CIDP
In the June JNNP issue, Koike and colleagues have reported the morphological changes in sural nerve biopsies of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who have autoantibodies against paranodal structures. CIDP is an immune-mediated neuropathy that develops over 8 week, which manifests with progressive proximal and distal weakness and is associated with sensory […]
Corpus callosum dysfunction in ALS: more than just connecting two sides
In the May JNNP issue, Zhang and colleagues have published a study investigating the changes in structural and functional connectivity in patients with ALS. ALS is one of the most complex neurodegenerative diseases, which affects the motor system. It is characterized by concomitant degeneration of the upper and lower motor neurons, producing progressive weakness […]
Prognostic factors in C9orf72 ALS: the battle of genders?
The C9orf72 hexanucleotide repeat expansion has been defined as the main genetic factor in amyotrophic lateral sclerosis (ALS), particularly across the ALS-frontotemporal dementia (FTD) continuum. Clinically, the C9orf72-related ALS cases have several distinct features including an earlier age of onset, reduced survival, higher prevalence of bulbar onset and dementia, contributing to the broad clinical […]
Immunomodulatory therapy modulates progression in advanced multiple sclerosis
In the current issue of JNNP, Lizak and colleagues have published an interesting epidemiological study based on global multiple sclerosis (MS) database (MSBase), to evaluate prognostic factors in moderately advanced and advanced MS, specifically the impact of highly active immunomodulatory therapy. Using prospectively collected data from over 4000 patients with MS, the cohort was […]